Severity of the Toxicity Associated With Combinations That Include Didanosine Plus Stavudine in HIV-Infected Experienced Patients

Background:The combination of didanosine (ddI) and stavudine (d4T) is no longer recommended as a first-line treatment because of toxicity, but it may be useful in experienced patients. Methods:Retrospective chart review of experienced patients on ddI plus d4T was conducted at a single institution, recording the development of adverse events as well as their severity and action taken. The risk of developing severe toxicities was estimated by Kaplan-Meier analysis. Results:A total of 616 patients were on ddI plus d4T for a median time of 12 months (interquartile range: 5.0-24.7 months). Among them, 213 (34.6%) had AIDS, 161 (27.4%) had CD4 counts <200 cells/mm3, and 503 (81.2%) had >2 previous treatment failures. Adverse events related to ddI plus d4T were recorded in 136 patients (22.1%), which were mild to moderate in 118 (19.1%) patients and severe in 18 (2.9%) patients. The mean times to development of severe and nonsevere adverse events were 72 (95% confidence interval [CI]: 70 to 75) weeks and 52 (95% CI: 48 to 55) weeks, respectively. The probability of developing severe adverse events was related to the nadir CD4 count, with higher risk in patients with <200 cells/mm3 (log rank test, P = 0.045). Conclusions:Multiexperienced patients treated with combinations, including ddI plus d4T, frequently develop drug-related toxicity, but these events are rarely severe. Thus, these drugs can still be considered a valid option for salvage regimens.

[1]  B. Clotet,et al.  Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy , 2005, Antiviral therapy.

[2]  V. Calvez,et al.  Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. , 2005, The Journal of infectious diseases.

[3]  S. Hammer,et al.  Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. , 2004, JAMA.

[4]  Colombe Chappey,et al.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.

[5]  M. Moroni,et al.  A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients , 2003, AIDS.

[6]  Marina Núñez,et al.  SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals , 2002, HIV clinical trials.

[7]  M. Law,et al.  Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study , 2002, HIV clinical trials.

[8]  D. Peterson,et al.  A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)* , 2000, AIDS.

[9]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[10]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[11]  A. Cross,et al.  Clinical Efficacy of Monotherapy with Stavudine Compared with Zidovudine in HIV-Infected, Zidovudine-Experienced Patients , 1997, Annals of Internal Medicine.

[12]  C. Pettinelli,et al.  2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. , 1990, The New England journal of medicine.